Introduction {#Sec1}
============

Osteoporosis is a chronic disease characterized by low bone mass and deterioration of bone tissue associated with an increased risk for fracture \[[@CR1]\]. People living with osteoporosis face reduced quality of life and loss of mobility and autonomy \[[@CR2]\]. Worldwide, at least one in three women and one in five men over the age of 50 years will sustain an osteoporotic fracture during their lifetime. Clinical practice guidelines have been developed in most jurisdictions and provide country-specific frameworks for osteoporosis management and fracture prevention to clinicians, patients, and healthcare administrators \[[@CR3], [@CR4]\].

Patient engagement is essential for the development of high-quality and relevant clinical practice guidelines. Scientific and patient organizations and research funding bodies have urged greater patient participation in knowledge synthesis and research activities, emphasizing the important stake that patients have in the outcomes and endorsing patients' unique experiences and valuable perspectives. The Guidelines International Network and the National Academy of Medicine recommend that patients or patient representatives be engaged on guideline development panels alongside physicians, researchers, and other professionals \[[@CR5], [@CR6]\]. Patient participation influences the inclusion of patient-relevant topics, outcomes selection, and approaches to recommendation development \[[@CR7]\].

Nevertheless, patient and public involvement in guideline development remains suboptimal \[[@CR8]\]. There are challenges to engaging patients in research and guideline development including recruiting patients, inadequate training and support, difficulties in understanding medical terminology, lack of resources for patients' engagement, and uncertainty of how to incorporate patient experiences into evidence-based guidelines \[[@CR7], [@CR9], [@CR10]\]. To overcome these barriers, strategies such as involving trained professionals for recruitment, clear communication, clarity regarding the patient role, and early engagement of patients throughout the entire guideline process have been proposed \[[@CR11]\].

Osteoporosis Canada is currently updating its national clinical practice guidelines using the GRADE framework \[[@CR12]\] and has been successful in assuring active patient collaboration throughout the entire process. Founded in 2004 by four friends who were determined to overcome the challenges of living with osteoporosis, the Canadian Osteoporosis Patient Network (COPN) is the patient arm of Osteoporosis Canada (OC). Within OC, COPN has an organizational structure, receives OC staff support, and participates actively in knowledge transfer activities, in white paper development and as an advisory body to national research funding bodies. Some of its members are actively involved as patient-partners in peer-reviewed research and quality of care improvement programs. COPN connects individuals affected by osteoporosis, communicates information about how to live well with the disease, and advocates for comprehensive access to diagnosis, treatment, and care. Its membership has recently reached 10,000 individuals across the country (<https://osteoporosis.ca/bone-health-osteoporosis/living-with-the-disease/copn/>).

As part of OC guideline update process, COPN members are active and engaged participants of the steering, conflict of interest and knowledge transfer committees, and of each of 4 working groups tasked with the development of key recommendation questions and systematic reviews \[[@CR13]\]. To inform the search strategy for knowledge syntheses and the eventual development of the clinical recommendations, COPN members have participated in the development, distribution, and evaluation of an electronic survey of their national membership with the primary objective to identify issues important to people living with osteoporosis in the development of the clinical guidelines. We report the survey results which presently informs the OC osteoporosis management guidelines update process.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

A self-administered online survey was developed and distributed using electronic mail to 6937 COPN members with email access from April 17 to May 8, 2018. COPN members were notified twice of the survey's imminent release through the distribution of an e-newsletter. The survey was distributed in a separate e-blast to ensure its visibility. A reminder to complete the survey was sent 2 weeks after the initial invitation. The survey was posted on SurveyMonkey™ (SurveyMonkey Inc., Palo Alto, CA, USA), an online survey development cloud-based software, is compliant with Canadian privacy and accessibility standards (W3C), and does not collect computer internet protocol (IP) address or any other participant identifying information. Consent to participate was assumed if the survey was completed and submitted. The study was approved by the University of Manitoba Health Research Ethics Board.

Survey design {#Sec4}
-------------

The survey was developed by the OC osteoporosis guideline steering committee including clinicians, patients, and researchers with expertise in bone health as well as in survey and guidelines development. Questions were developed to engage participants by using specific web-based survey design, structure, and technical interface \[[@CR14]\] and were designed to acquire input about the future guidelines' content and selection of research questions. There were 10 close-ended questions and 2 open-ended questions. Three questions pertained to limited demographic information and to knowledge about osteoporosis (very little knowledge, a little knowledge, neutral, somewhat knowledgeable, very knowledgeable), three questions inquired about the importance of including guidance on specific recommendations and clinical outcomes (1--2, not important to consider; 3--4, important; 5, critical to consider), two questions focused on how to get information about fracture risk assessment and healthcare provider visit, and two questions were on exercise and medication and had a free text box to allow for additional comments ([Supplemental Appendix](#MOESM1){ref-type="media"}- survey). Participants were asked for inputs and comments through 2 open-ended questions: (1) Provide up to three specific questions that you would like to see addressed in the next Canadian Osteoporosis Clinical Practice Guidelines and (2) What questions do you have about the safety or effectiveness of exercise, or safe performance of physical activities of leisure or daily living. Clarity, content, and interface validity of the survey were verified through pilot testing with 53 participants. Recommended changes were incorporated into the final survey prior to distribution. The survey was translated into French for distribution to COPN French-speaking members.

Analysis {#Sec5}
--------

Data were analyzed using descriptive statistics for close-ended questions with results expressed as frequencies and percentages.

Content analysis was conducted for the open-ended questions using NVivo software version 11 by QSR International Ltd. \[[@CR15], [@CR16]\]. Initial step of content analyses consisted of preliminary reading of raw data to recognize respondents' perceptions. Primary coding level of raw data was conducted for each question by identifying every idea. Identified ideas were coded by simple induction \[[@CR17]\] without predetermined themes or research-based expectations \[[@CR18]\]. Second level of coding was focused on grouping the ideas to create categories described as inductive analyses of codes to create categories or subthemes. Finally, thematic coding as a third level of analyses studied previous coding to develop highly refined themes representing a group of categories of ideas. Two independent researchers coded the data using described qualitative analyses methodology based on content analyses. Figures for close-ended questions were generated using GraphPad Prism ver. 6.0 (La Jolla, CA, USA).

Results {#Sec6}
=======

A total of 1108 completed surveys were obtained (16% participation rate from 6937 members with electronic email addresses). Most respondents were women (96%, *N* = 1059) and 85% reported living with osteoporosis, 84% of the men respondents also reported having osteoporosis; 4.8% claimed to be an allied health professional and 0.6% to be a physician. Sixty-one percent of respondents had some knowledge about osteoporosis while 24% reported to be very knowledgeable and 1.3% to have very little knowledge. The majority of participants were from the provinces of Ontario (*N* = 534) and British Columbia (*N* = 186), with less than 100 participants from each of the other provinces and territories. Not all participants answered all questions (range 10 to 123 responses missing per question) (Table [1](#Tab1){ref-type="table"}).Table 1Survey participants' characteristicsParticipants' characteristics*N* = 1108Sex, *n* (%)  Women1059 (96%)Language, *n* (%)  English1036 (94%)Osteoporosis, *n* (%)  I have OP943 (86%)  I care for someone with OP29 (3%)Place of residence of participants in Canada (%)  Western Canada34%  Central Canada58%  Atlantic Canada8%  Northern Canada\< 1%Osteoporosis knowledge (%)  Knowledgeable^1^85%  Not knowledgeable^2^15%^1^Knowledgeable includes very knowledgeable and knowledgeable; ^2^Not knowledgeable includes little knowledgeable, very little knowledgeable, or neutral

Most participants considered it critical (5 on a 5-point rating scale) to have recommendations on physical activity and exercise (74%), fall prevention (69%), nutrition (68%), initial bone mineral density testing (67%), and management of acute pain from fractures (66%) (Fig. [1a](#Fig1){ref-type="fig"}). The weighted averages for responses for these recommendations were all above 4.5, with less than 2% choosing the category of "not important to consider".Fig. 1Percentage of respondents who indicated that specific recommendations (**a**) and outcomes (**b**) were critical to consider in the updated osteoporosis clinical guideline development

Over 75% of respondents stated that preserving quality of life and well-being (87%) and ability to perform daily physical and social activities (84%), preventing admission to long-term care (84%) and fracture-related death (85%), preventing all fractures (79%), and avoiding serious harms from medications (78%) were critical outcomes to consider in guidelines development (Fig. [1b](#Fig1){ref-type="fig"}). The weighted averages for responses for these recommendations were all above 4.7, with less than 1.5% choosing the category of "not important to consider".

Discussion with a physician (average 4.2) or with another healthcare professional (average 4.1), or access to material posted on the OC website (average 4.1), was determined to be critical in ensuring a good understanding of the risks and consequences of fractures by 51%, 41%, and 41% of the respondents respectively. The majority of participants (64%) would be willing to spend 15 min to 1 h preparing themselves for a visit and discussion with their physician on fracture risk and 55% felt they would likely require a discussion of more than 10 min with their physician to understand the result of their fracture risk assessment.

Results of the close-ended question on exercise (why do you choose to participate in exercise? enter up to 5 answers) revealed that most respondents chose to exercise for its effect on balance (77%), strength (64%), mobility (53%), and quality of life (51%). Other benefits were also noted to be of importance: effect on posture (45%), on preservation of BMD (42%), on endurance (43%), on risk of falls or broken bones (42%), and on the ability to do daily exercises (41%). The effect of exercise on mood was felt to be important only for a minority (11%). In addition to those pre-specified answers in the exercise close-ended question, 7% of participants provided comments in the "Other" answer box generating 63 references. Key issues identified included benefits of exercise on general health (19 references: autonomy, strength, balance and flexibility, social interactions, well-being, and pain reduction), benefits of exercise on the skeleton (16 references: safety of exercises/movements, what exercises improve BMD, and optimal exercise frequency), and barriers to exercising (20 references: lack of access to facilities/trained professionals, perceived difficulty due to pain, lack of time, negative attitudes towards exercise, and lack of guidance by primary care professionals).

We specifically inquired whether participants had specific questions about the safety or effectiveness of exercise in an open-ended question (Table [2](#Tab2){ref-type="table"}). Three hundred sixty-eight participants provided 586 references, most pertained to what exercises or types of exercise (e.g., yoga) were safe versus what to avoid (*n* = 222) and what type or dose of exercises was effective (*n* = 145). There was significant interest in how to access safe and effective exercises (e.g., online videos, community groups, trained professionals; *n* = 116). In addition, participants were interested to know more about the benefits of exercise on bone mineral density, fracture risk, balance and strength, as well as pain and quality of life.Table 2Participants' responses to the open-ended question: What questions do you have about the safety or effectiveness of exercise, or safe performance of physical activities of leisure or daily living?Number of participants who provided answers*N* = 368Total references\*\
586How can I exercise safely?222  Safety of specific/preferred exercises (yoga etc.)  What exercises to avoid  What exercises/classes/movements are safe to do  Concerns about adverse effects (including pain)  If I have a vertebral fracture6956533114How can I exercise effectively?145  Best/most effective exercises for my condition  Right frequency/duration/intensity of exercise/strength training8857How can I access safe and effective exercises?116  Trained professionals  Make adapted exercises available online/on video/at home  Community/support groups/age-specific classes483533What are the benefits of exercise on:72  Bone mineral density  Fracture risk  Balance and strength  Pain and quality of life improvement23231511Other31\*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question

We asked participants to select up to 5 items from a list of questions or issues related to medications for osteoporosis they would like addressed in the updated guidelines to help guide healthcare professionals in making treatment decisions with their patients. The most frequently noted items were as follows: how to choose the best medication option (81%), how to describe the risks and benefits of each medication (81%), how long a medication should be taken (67%), how to tell if a medication is working (65%), and how to watch for side effects including common and rare events (65%). A free text box allowed respondents to provide additional input leading to 135 references (Table [3](#Tab3){ref-type="table"}). Most responses were related to pharmacological treatment (75 references) with 73% of references related to benefits and harms of the medications. Furthermore, there was interest in ensuring that guidance was provided to healthcare professionals about nutritional supplements (*n* = 19) and alternative therapies (e.g., natural products, naturopathy; *n* = 14).Table 3Participants' responses to the open-ended question: What questions or issues related to medications for osteoporosis would you like to see addressed in the next Canadian Osteoporosis Clinical Practice Guidelines in order to help doctors and other healthcare professionals in making treatment decisions with their patients?Number of participants who provided answers*N* = 113Total references\*\
135Pharmacologic treatment75  Benefits and harms55  Cost of medications7  Drug-drug interactions5  New medications4  Drug holiday2  Access to medications1  Time to start with a therapy1Nutrition and supplements19  Supplements recommendations12  Dietary recommendations7Alternative therapies14Education11  For patients/families/caregivers---source of information they can trust6  For healthcare professionals5Monitoring-prevention8  Response to treatment/BMD6  Prevention1  Access to specialists1Pain management6Other2\*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question

Table [4](#Tab4){ref-type="table"} summarizes results of content analyses for suggestions of research questions for consideration for evidence synthesis ("Provide up to three specific questions you would like to see addressed in the next Canadian Osteoporosis Clinical Practice Guidelines"). Participants provided 964 references that emerged into 8 main themes that we tabulated in descending order of importance: pharmacological treatment (e.g., benefits and harms, new medications, duration of therapy, drug holiday); screening, monitoring, and prevention (BMD testing); nutrition and supplements; exercise and physical activity; knowledge, education, and advocacy; alternative therapies; and pain. One-third of the participants' responses (327 references) were related to pharmacological treatments including benefits and harms, new medications or the best medication, duration of therapy, as well as drug holiday.Table 4Participants' responses to the open-ended question: Provide up to three specific questions you would like to see addressed in the next Canadian Osteoporosis Clinical Practice GuidelinesNumber of participants who provided answers*N* = 498Total references\*\
964Pharmacological treatment327  Benefits and harms183  New medications/the best medication58  Duration of therapy/drug holiday54  Other (cost, medication choice, etc.)32Screening-monitoring-prevention193  BMD tests/response to treatment88  Prevention65  Early screening30  Other (access to specialists, clinics, etc.)10Nutrition and supplements140  Dietary recommendations59  Supplements recommendations52  Dietary sources of calcium22  Other (vitamin K, protein)7Exercise-physical activity121  Recommendations80  Safety and benefits31  Other (fit trainers, cost, etc.)10Knowledge-education-advocacy135  Patients/families/caregivers72  Healthcare professionals22  Advocacy/support groups17  General public13  Other (list of specialists, funding, etc.)11Alternative therapies30  Naturopathy/natural products28  Other2Pain18  Pain management15  Cannabis2  Other (osteoporosis pain vs. arthritis pain)1\*Each participant could give more than one idea: 1 idea = 1 reference. Total indicates the number of references among the participants who answered the open-ended question

Finally, we separately analyzed the answers provided by the men respondents and found no differences when compared with those provided by women respondents.

Discussion {#Sec7}
==========

We engaged patients as partners in priority setting to inform the development of national osteoporosis guidelines and learned that recommendations on pharmacotherapy, screening and monitoring, nutrition, and exercise were fundamental in the upcoming guidelines. However, in addition to fracture prevention, over 75% of participants responded that outcomes such as preservation of autonomy, mobility, and quality of life were essential to consider when developing recommendations for osteoporosis management.

Mobility can be seriously diminished in patients with osteoporosis, particularly in those who have sustained fractures \[[@CR19]\]. Kerr et al. have also documented, through patient and clinician interviews, the importance of the impact of osteoporosis on physical function \[[@CR20]\]. They described a cycle of impairment characterized by the interaction of numerous factors such that limitations in activities lead to loss of muscle and bone strength with a subsequent increase in fracture risk, which in turn will result in pain and fear of falling and further limitations in the performance of daily activities. This accumulation of physical impairments and fear can precipitate institutionalization and dependence on others for simple tasks. Our findings were similar in that mobility and autonomy were highly valued by respondents of this survey.

Participants identified physicians and healthcare professionals as their preferred source of information on osteoporosis and fractures and they are agreeable to spending a significant amount of time to prepare for a physician visit and to discuss the results of fracture risk assessment. Therefore, in addition to guideline development, we will engage in the development and implementation of tools to support knowledge transfer and shared decision-making at the time of the guidelines publication.

Evidence of consideration for patient beliefs, values, and preferences is often not provided in osteoporosis clinical practice guidelines \[[@CR21]\]. In a recent review of seventy international guidelines, only 39% included statements about patients' values and preferences; most of these statements were conceptualized as preferences for one medication over another or in terms of financial costs of therapies. To complicate matters, ascertainment and understanding of patient preferences can differ between patients and guideline developers such that, for example, one would consider options in terms of treatment (including no treatment) while the other would expect choices between various treatments \[[@CR22]\]. Although respondents in our survey mentioned specific questions on pharmacotherapy with high frequency, a variety of other considerations such as exercise, diet, education and alternative therapies, and pain were also noted, expanding the field of interest outside of the traditional pharmacologic focus.

Accurate perception of risk is crucial for the rational adoption of treatment. Communicating risk and benefit of pharmacological treatment to patients remains a great challenge \[[@CR23]\]. Many tools and strategies \[[@CR24]\], developed by investigators (such as the Mayo Clinic Osteoporosis Choice decision aid <https://osteoporosisdecisionaid.mayoclinic.org/index.php/site/index>) and patient societies, aim to support decision-making; however, in our experience and as has been highlighted in recent publications \[[@CR25]\], healthcare providers' messages about fracture risk are confusing to patients and much work is still required so that communications better suit patients' needs.

The patient perspective is now recognized as fundamental in health research, guideline development, and treatment regulatory processes and recommended by many organizations \[[@CR26]\]. Growing recognition that people with lived experience can make important contributions to the study of health and healthcare has resulted in increasing participation of patients in different levels of involvement from consultation such as surveys and interviews to active engagement like shaping research questions. OC is fortunate to count on its COPN members' involvement in the updating of the clinical guidelines and in many other research activities. Future research protocols may also benefit from this type of background data to inform study design and outcomes that are important to patients beyond simple measures of fracture occurrence. Our ongoing engagement will support the successful creation of relevant practice guidelines that incorporate patients' values and perspectives and encourage shared decision-making.

Our study is limited by the modest response rate and the fact that those who answered likely constitute a select group with a special interest in guideline development and engagement in such projects. Very few men participated in the survey. Still, over one thousand COPN members responded to the survey request, which is a very large number of respondents for a non-remunerated patient survey. Furthermore, the respondents' demographics are representative of the national COPN membership, supporting the robustness of our data.

Also, most respondents claimed to have at least some background knowledge of osteoporosis with many being very knowledgeable. It is therefore possible that less-engaged patients may be less willing to do pre-visit "homework" in preparation for a physician visit. Novel knowledge translation approaches may be necessary to make pre-visit educational preparation accessible and customizable for those who are less inclined to seek out educational resources on their own.

In conclusion, patients emphasized that autonomy, mobility, and quality of life are highly valued outcomes and must be integral to practice guideline development. As expected, guidance on pharmacotherapy, screening and monitoring, and fracture prevention were priorities identified to be included in osteoporosis management guidelines. The results of this national patient survey on content, outcomes, and key questions are essential for OC osteoporosis guidelines update process, but more importantly, this exercise emphasizes the value of patient engagement as expert-partners in the development of osteoporosis prevention and management strategies.
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